103 related articles for article (PubMed ID: 35754442)
1. Pembrolizumab-Induced Acute Skin Reaction: A Case Report and Review of Literature.
Thomas M; Wazir A; Poudel A
Cureus; 2022 Jun; 14(6):e26143. PubMed ID: 35754442
[TBL] [Abstract][Full Text] [Related]
2. Association of Programmed Cell Death 1 Inhibitor with Circumorificial Plasmacytosis.
Tanimu Y; Coombs R; Tanimu S; Onitilo A
Case Rep Oncol; 2024; 17(1):33-38. PubMed ID: 38188483
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab-Induced Lichen Planus in a Patient With Non-Small-Cell Lung Carcinoma (NSCLC) That Correlates to Therapeutic Response.
Sehbai A; Hamid MA; Ibrahim Z
Cureus; 2022 Nov; 14(11):e31454. PubMed ID: 36523676
[TBL] [Abstract][Full Text] [Related]
4. Scleroderma Secondary to Pembrolizumab: A Case Report and Review of 19 Cases of Anti-PD-1-Induced Scleroderma.
Farrugia S; Mercieca L; Betts A; Refalo N; Boffa MJ
Case Rep Oncol; 2023; 16(1):846-856. PubMed ID: 37900813
[TBL] [Abstract][Full Text] [Related]
5. Scleroderma-like Syndrome in the Setting of Pembrolizumab Therapy for Non-Small Cell Lung Cancer: Diagnosis and Dermatologic Management.
Fattore D; Battista T; De Lucia M; Annunziata MC; Fabbrocini G
Case Rep Dermatol; 2022; 14(2):225-229. PubMed ID: 36158854
[TBL] [Abstract][Full Text] [Related]
6. Psoriasis induced by first‑line pembrolizumab in metastatic non‑small cell lung cancer: A case report.
Gatti F; Caruso G; Potenza C; Santini D; Petrozza V; Annetta A; Ceddia S; Cosimati A; Brandi M; Sorrentino V; Proietti I; Rossi L
Oncol Lett; 2023 Jul; 26(1):311. PubMed ID: 37332334
[TBL] [Abstract][Full Text] [Related]
7. A case report involving suppressed nuclear receptor transcription factors 4a1 and Stevens-Johnson syndrome induced by a single dose of pembrolizumab and successfully treated with early steroid administration, resulting in complete remission of stage III lung cancer.
Machida M; Yamazaki C; Kouda N; Hanai Y; Sato H; Konda A; Yamagata Y; Itho T; Aisaka H
J Pharm Health Care Sci; 2022 Dec; 8(1):29. PubMed ID: 36464708
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab-Induced Lichen Planus: A Rare Immune-Related Adverse Side Effect.
Bansal A; Singla A; Paul D; Kaur S
Indian Dermatol Online J; 2023; 14(3):391-394. PubMed ID: 37266094
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab-Induced Vitiligo in Esophageal Squamous Cell Carcinoma Patient With Durable Complete Response.
Wilkins MC; Elgamal M; Rybkin II
Cureus; 2021 Nov; 13(11):e19739. PubMed ID: 34938618
[TBL] [Abstract][Full Text] [Related]
10. Acute Non-infectious Cystitis Secondary to Immune-Related Adverse Events in a Patient Receiving Pembrolizumab for Treatment of Non-small Cell Lung Cancer: A Case Report.
Alhusari L; Abdallah M; Nwanwene K; Shenouda M
Cureus; 2024 Mar; 16(3):e55666. PubMed ID: 38586668
[TBL] [Abstract][Full Text] [Related]
11. Case report: Pharmacokinetics of pembrolizumab in a patient with stage IV non-small cell lung cancer after a single 200 mg administration.
de Vries F; Smit AAJ; Wolbink G; de Vries A; Loeff FC; Franssen EJF
Front Oncol; 2022; 12():960116. PubMed ID: 36713570
[TBL] [Abstract][Full Text] [Related]
12. Steroid-Refractory Lichenoid Eruption Associated with Pembrolizumab in a Patient with Non-Small Cell Lung Cancer.
Kou L; Agarwal S; Miceli A; Kolb L; Krishnamurthy K; Schmieder S
HCA Healthc J Med; 2021; 2(6):397-400. PubMed ID: 37427397
[TBL] [Abstract][Full Text] [Related]
13. Adverse Endocrine-Related Effects of Pembrolizumab Precipitating Severe Hyponatremia.
Baldawi MB; Dhami B; Gosai J; Al-Khafaji RH
Cureus; 2022 Aug; 14(8):e28393. PubMed ID: 36171843
[TBL] [Abstract][Full Text] [Related]
14. A Case of Melanoma-Associated Retinopathy, Uveitis, and Optic Neuritis Associated With Pembrolizumab, Managed With Topical, Intravitreal, and Intravenous Steroids.
Xie K; Kong C; Mehta MC
J Vitreoretin Dis; 2020 Jun; 4(3):220-226. PubMed ID: 37007447
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab-induced secondary adrenal insufficiency due to adrenocorticotrophic hormone deficiency in a patient with non-small-cell lung carcinoma: a case report.
Fujimiya T; Azuma K; Togashi Y; Kuwata K; Unezaki S; Takeuchi H
J Pharm Health Care Sci; 2024 Feb; 10(1):10. PubMed ID: 38365819
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab-induced asthma exacerbation with hypereosinophilia and elevated interleukin-5 in endometrial cancer: A case report.
Harada T; Uetani N; Inui G; Ishikawa H; Funaki Y; Takata M; Okazaki R; Yamaguchi K; Morita M; Kitatani S; Yamasaki A
Respir Med Case Rep; 2024; 49():102035. PubMed ID: 38712312
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitor-associated arthritis in advanced pulmonary adenocarcinoma: A case report.
Yang Y; Huang XJ
World J Clin Cases; 2022 Oct; 10(29):10701-10707. PubMed ID: 36312471
[TBL] [Abstract][Full Text] [Related]
18. Acute pancreatitis associated with pembrolizumab-induced hypertriglyceridemia.
Inayat F; Afzal A; Anwar MS; Saeed A; Chaudhry A; Haider M; Zulfiqar L; Afzal MS; Arslan HM; Saif MW
J Oncol Pharm Pract; 2024 Apr; ():10781552241245332. PubMed ID: 38576329
[TBL] [Abstract][Full Text] [Related]
19. Non-bacterial cystitis with increased expression of programmed death-ligand 1 in the urothelium: An unusual immune-related adverse event during treatment with pembrolizumab for lung adenocarcinoma.
Ueki Y; Matsuki M; Kubo T; Morita R; Hirohashi Y; Sato S; Horibe R; Matsuo K; Tsukahara T; Kanaseki T; Takakuwa Y; Satoh M; Itoh N; Torigoe T
IJU Case Rep; 2020 Nov; 3(6):266-269. PubMed ID: 33163921
[TBL] [Abstract][Full Text] [Related]
20. Long-term complete remission after severe pembrolizumab-induced immune-related encephalitis in metastatic lung adeno-squamous carcinoma: A case report.
Quirynen R; Ocak S; Duplaquet F; Pirard L
Respir Med Case Rep; 2023; 45():101898. PubMed ID: 37577125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
